These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 38478885)
1. Structure-Guided Design and Optimization of Covalent VHL-Targeted Sulfonyl Fluoride PROTACs. Shah RR; De Vita E; Sathyamurthi PS; Conole D; Zhang X; Fellows E; Dickinson ER; Fleites CM; Queisser MA; Harling JD; Tate EW J Med Chem; 2024 Mar; 67(6):4641-4654. PubMed ID: 38478885 [TBL] [Abstract][Full Text] [Related]
2. Journey of Von Hippel-Lindau (VHL) E3 ligase in PROTACs design: From VHL ligands to VHL-based degraders. Setia N; Almuqdadi HTA; Abid M Eur J Med Chem; 2024 Feb; 265():116041. PubMed ID: 38199162 [TBL] [Abstract][Full Text] [Related]
3. A beginner's guide to current synthetic linker strategies towards VHL-recruiting PROTACs. Zografou-Barredo NA; Hallatt AJ; Goujon-Ricci J; Cano C Bioorg Med Chem; 2023 Jun; 88-89():117334. PubMed ID: 37224698 [TBL] [Abstract][Full Text] [Related]
4. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones. Ishida T; Ciulli A SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537 [TBL] [Abstract][Full Text] [Related]
5. Targeted Protein Degradation through E2 Recruitment. Forte N; Dovala D; Hesse MJ; McKenna JM; Tallarico JA; Schirle M; Nomura DK ACS Chem Biol; 2023 Apr; 18(4):897-904. PubMed ID: 36940189 [TBL] [Abstract][Full Text] [Related]
6. Development of versatile solid-phase methods for syntheses of PROTACs with diverse E3 ligands. Xu H; Kurohara T; Ohoka N; Tsuji G; Inoue T; Naito M; Demizu Y Bioorg Med Chem; 2023 May; 86():117293. PubMed ID: 37126968 [TBL] [Abstract][Full Text] [Related]
7. Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs. Girardini M; Maniaci C; Hughes SJ; Testa A; Ciulli A Bioorg Med Chem; 2019 Jun; 27(12):2466-2479. PubMed ID: 30826187 [TBL] [Abstract][Full Text] [Related]
8. Expanding the ligand spaces for E3 ligases for the design of protein degraders. Shah Zaib Saleem R; Schwalm MP; Knapp S Bioorg Med Chem; 2024 May; 105():117718. PubMed ID: 38621319 [TBL] [Abstract][Full Text] [Related]
9. Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications. Ward CC; Kleinman JI; Brittain SM; Lee PS; Chung CYS; Kim K; Petri Y; Thomas JR; Tallarico JA; McKenna JM; Schirle M; Nomura DK ACS Chem Biol; 2019 Nov; 14(11):2430-2440. PubMed ID: 31059647 [TBL] [Abstract][Full Text] [Related]
11. Target protein localization and its impact on PROTAC-mediated degradation. Simpson LM; Glennie L; Brewer A; Zhao JF; Crooks J; Shpiro N; Sapkota GP Cell Chem Biol; 2022 Oct; 29(10):1482-1504.e7. PubMed ID: 36075213 [TBL] [Abstract][Full Text] [Related]
12. Combinatorial Ubiquitination REal-time PROteolysis (CURE-PROs): A Modular Platform for Generating Reversible, Self-Assembling Bifunctional Targeted Degraders. Giardina SF; Valdambrini E; Singh PK; Bacolod MD; Babu-Karunakaran G; Peel M; Warren JD; Barany F J Med Chem; 2024 Apr; 67(7):5473-5501. PubMed ID: 38554135 [TBL] [Abstract][Full Text] [Related]
13. E3 ligase ligand chemistries: from building blocks to protein degraders. Sosič I; Bricelj A; Steinebach C Chem Soc Rev; 2022 May; 51(9):3487-3534. PubMed ID: 35393989 [TBL] [Abstract][Full Text] [Related]
14. Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders. Diehl CJ; Ciulli A Chem Soc Rev; 2022 Oct; 51(19):8216-8257. PubMed ID: 35983982 [TBL] [Abstract][Full Text] [Related]
15. Optimization of Potent Ligands for the E3 Ligase DCAF15 and Evaluation of Their Use in Heterobifunctional Degraders. Lucas SCC; Ahmed A; Ashraf SN; Argyrou A; Bauer MR; De Donatis GM; Demanze S; Eisele F; Fusani L; Hock A; Kadamur G; Li S; Macmillan-Jones A; Michaelides IN; Phillips C; Rehnström M; Richter M; Rodrigo-Brenni MC; Shilliday F; Wang P; Storer RI J Med Chem; 2024 Apr; 67(7):5538-5566. PubMed ID: 38513086 [TBL] [Abstract][Full Text] [Related]
16. A "Click Chemistry Platform" for the Rapid Synthesis of Bispecific Molecules for Inducing Protein Degradation. Wurz RP; Dellamaggiore K; Dou H; Javier N; Lo MC; McCarter JD; Mohl D; Sastri C; Lipford JR; Cee VJ J Med Chem; 2018 Jan; 61(2):453-461. PubMed ID: 28378579 [TBL] [Abstract][Full Text] [Related]
17. Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design. Krieger J; Sorrell FJ; Wegener AA; Leuthner B; Machrouhi-Porcher F; Hecht M; Leibrock EM; Müller JE; Eisert J; Hartung IV; Schlesiger S ChemMedChem; 2023 Apr; 18(8):e202200615. PubMed ID: 36749883 [TBL] [Abstract][Full Text] [Related]
18. Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins. Yokoo H; Tsuji G; Inoue T; Naito M; Demizu Y; Ohoka N Bioorg Chem; 2024 Apr; 145():107204. PubMed ID: 38377822 [TBL] [Abstract][Full Text] [Related]
19. Exploiting the Cullin E3 Ligase Adaptor Protein SKP1 for Targeted Protein Degradation. Hong SH; Divakaran A; Osa A; Huang OW; Wertz IE; Nomura DK ACS Chem Biol; 2024 Feb; 19(2):442-450. PubMed ID: 38305738 [TBL] [Abstract][Full Text] [Related]
20. Targeted Protein Degradation through Recruitment of the CUL4 Complex Adaptor Protein DDB1. Meyers M; Cismoski S; Panidapu A; Chie-Leon B; Nomura DK ACS Chem Biol; 2024 Jan; 19(1):58-68. PubMed ID: 38192078 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]